# BioCorRx Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/BioCorRx Inc.).

## Overview

BioCorRx Inc. is a U.S.-based specialty outpatient services and pharmaceutical distribution company that has historically operated addiction recovery and weight-loss related programs, while more recently adding Lucemyra® distribution sales. Its reported revenue streams include clinic access fees, membership/program fees, distribution rights income, and supply/distribution net sales tied to exclusive and nonexclusive distribution agreements. The company also operates through BioCorRx Pharmaceuticals, Inc., which entered into distribution arrangements as part of the USWM LLC Asset Purchase Agreement in March 2025. Despite the new revenue activity, the company remains in an early, financially stressed stage and has disclosed substantial doubt about its ability to continue as a going concern.

## Products & services

• Lucemyra® distribution sales and supply arrangements
• Sales/access fees for licensed clinics
• UnCraveRx™ weight loss management program
• Distribution rights income from licensing arrangements
• Pharmaceutical distribution profit-share arrangements

- **Pharmaceutical distribution** (88%) — Supply and distribution of Lucemyra® and related product sales under exclusive and nonexclusive agreements.
- **Clinic access services** (6%) — Fees earned from patients treated at licensed clinics that use the company's recovery-related service model.
- **Membership and wellness programs** (0%) — Program fees from the UnCraveRx™ weight loss management offering and related membership services.
- **Distribution rights and licensing** (6%) — Income recognized from rights granted to counterparties and amortization of deferred license revenue.

- Lucemyra® distribution sales and supply arrangements
- Sales/access fees for licensed clinics
- UnCraveRx™ weight loss management program
- Distribution rights income from licensing arrangements
- Pharmaceutical distribution profit-share arrangements

## Customers

BioCorRx sells to a mix of clinics, distributors, and end-market patients participating in its treatment and wellness programs. The clinic-related revenue comes from licensed clinics treating patients, which suggests a B2B-to-patient service model where the clinic is the paying counterparty and the patient is the end user. The newer Lucemyra® activity is tied to distribution partners under exclusive and nonexclusive agreements, making distributors and supply-chain counterparties an increasingly important customer group. The company also serves consumers enrolled in its UnCraveRx™ weight loss management program, although management disclosed that customer counts in that program have declined. Overall, demand appears fragmented and small-scale, with revenue sensitive to clinic utilization, distributor execution, and program enrollment.

- **Licensed clinics** (primary) — Clinics that generate sales/access fees when they treat patients under the company's licensed service model.
- **Pharmaceutical distribution partners** (primary) — Counterparties in exclusive and nonexclusive Lucemyra® distribution agreements that purchase supply or share profits from sales.
- **Program participants** (secondary) — Individuals enrolled in UnCraveRx™ and related wellness offerings that generate membership/program fees.
- **License and rights counterparties** (secondary) — Partners that pay for distribution rights or related licensing economics, including deferred revenue arrangements.

- Licensed clinics that pay access fees to use the company's treatment model
- Distribution partners that buy or resell Lucemyra® under supply agreements
- Patients treated at licensed clinics, which drive access-fee activity
- Consumers enrolled in UnCraveRx™ weight loss management programs
- Counterparties receiving distribution rights and sharing net distributable profits

## Geography

The company is headquartered in the United States and its reported revenue disclosures are U.S.-centric. The recent Lucemyra® distribution agreements and clinic activity described in the filings indicate that commercial execution, regulatory compliance, and reimbursement dynamics are primarily tied to the U.S. market. No country-level revenue split was disclosed in the provided excerpts, so the business profile should be viewed as concentrated in the domestic market. That concentration matters because the company’s small revenue base is exposed to U.S. healthcare utilization, distribution execution, and funding conditions. Any expansion beyond the U.S. would likely require additional regulatory, commercial, and capital resources.

- Headquartered in the United States
- Revenue disclosures in the excerpts are primarily U.S.-based
- Lucemyra® distribution agreements appear to be executed domestically
- Clinic and program activity depends on U.S. healthcare and consumer demand
- No country-level revenue split was disclosed in the provided excerpts

## Strategy

BioCorRx's near-term strategy appears centered on monetizing the Lucemyra® asset through distribution agreements while preserving its clinic and program-based revenue streams. Management highlighted several exclusive and nonexclusive distribution agreements entered into in connection with the USWM LLC Asset Purchase Agreement, indicating a shift toward product distribution and profit-share economics. At the same time, the company is still trying to sustain its legacy clinic access and UnCraveRx™ program activity, even though those lines have weakened. The filings also make clear that capital raising remains a strategic necessity, because the company cannot fund its operating plan from current cash alone. In practical terms, the strategy is about building a revenue bridge from small service revenues toward a more scalable distribution model, but execution and financing risk remain high.

- **Scale Lucemyra® distribution** (short-term) — The new distribution stream is the main source of recent revenue growth and is the clearest path to expanding sales.
- **Secure external financing** (short-term) — The company disclosed substantial doubt about going concern and said current cash will not fund the next twelve months.
- **Preserve legacy service revenue** (medium-term) — Clinic access fees and program fees provide diversification while the distribution model is still developing.

- Expand Lucemyra® distribution sales through new supply and distribution agreements
- Monetize exclusive and nonexclusive distribution rights tied to the USWM LLC asset purchase
- Maintain clinic access-fee revenue from licensed treatment sites
- Keep the UnCraveRx™ program active despite lower customer counts
- Raise additional capital through equity or outside financing to fund operations
- Use profit-share economics from distributors to improve revenue scalability

## Risks

BioCorRx faces substantial going-concern and liquidity risk because it has disclosed a working capital deficit, accumulated losses, and insufficient cash to fund projected operations. Its revenue base is still very small and volatile, with recent growth driven mainly by a new distribution arrangement rather than a broad recurring customer base. The company is also exposed to execution risk in pharmaceutical distribution, where revenue depends on counterparty performance, control transfer, and the satisfaction of a single performance obligation. Legacy clinic and program revenues have weakened, showing that demand can fall quickly if patient volumes or customer counts decline. More broadly, the company faces typical healthcare-services and small-cap biotech risks, including regulatory compliance, reimbursement sensitivity, financing dependence, and potential dilution from repeated capital raises.

- **Going concern and liquidity shortfall** [critical] — Management disclosed a working capital deficit, accumulated deficit, and insufficient cash to fund the next twelve months.
- **Dependence on Lucemyra® distribution execution** [high] — Recent revenue growth is driven primarily by new distribution sales, so any disruption in partner performance or supply could quickly reduce revenue.
- **Declining clinic and program demand** [medium] — The company reported fewer patients at licensed clinics and fewer customers in UnCraveRx™, reducing legacy revenue streams.
- **Dilution from equity financing** [high] — The company stated it will likely need to raise capital through common stock placements or outside financing.

- Going-concern risk from persistent losses and insufficient cash
- Dependence on external financing and shareholder advances
- Revenue concentration in a new Lucemyra® distribution stream
- Volatility in clinic access fees and program enrollment
- Revenue recognition risk in profit-share and supply arrangements
- Regulatory and compliance risk in healthcare and pharmaceutical distribution

## Accounting

Revenue recognition is a key accounting issue because the company now records multiple types of revenue, including clinic access fees, membership/program fees, distribution rights income, and supply/distribution net sales. Management specifically noted that under exclusive distribution and supply arrangements, services are not distinct and revenue is recognized as a single performance obligation, which affects timing and classification of revenue. The company also recognizes revenue from net distributable profits only when control transfers to the end customer and the performance obligation is satisfied, making reported revenue sensitive to contract terms and delivery milestones. Quarterly results can be highly uneven because new distribution sales have replaced smaller legacy revenue streams, while deferred license revenue has been fully amortized. In addition, the company’s income tax accounting relies on valuation allowances against deferred tax assets, and its debt discounts, related-party borrowings, and fair value liabilities can materially affect reported earnings in periods with limited operating income.

- **Revenue recognition for distribution agreements** — Can shift revenue between periods and affect gross margin presentation
- **Deferred revenue from distribution rights** — Affects reported revenue mix and comparability across quarters
- **Valuation allowance on deferred tax assets** — Can materially change tax expense and equity
- **Debt discount and related-party interest** — Can increase reported financing costs and net loss

- Revenue timing depends on whether distribution and supply are treated as one performance obligation
- Net distributable profit recognition depends on control transfer and contract completion
- Deferred license revenue amortization affects distribution rights income
- Quarterly revenue is volatile because new distribution sales can replace small legacy fees
- Valuation allowance judgments affect deferred tax asset recognition
- Debt discounts and related-party financing affect interest expense and net loss

---

*Last updated: 2026-08-11T04:46:23.765324+00:00*